scFv(EPCAM)-OX40-CD3zeta CAR-T Lentivirus

The scFv(EPCAM)-OX40-CD3ζ CAR-T lentivirus is a gene delivery system designed to produce second-generation chimeric antigen receptor (CAR) T cells that specifically target epithelial cell adhesion molecule (EpCAM). This lentiviral vector offers several significant technological advantages, most notably its ability to achieve high transduction efficiency in primary human T lymphocytes, which have historically been difficult to modify using non-viral methods. The integration of the CAR transgene into the host genome ensures stable and long-term expression, guaranteeing the delivery of the therapeutic receptor to all progeny cells during T cell proliferation. A key feature of this specific construct is the inclusion of an OX40 (CD134) co-stimulatory domain in addition to the CD3ζ activation signaling domain. Unlike the more common CD28 or 4-1BB domains, the OX40 signaling pathway is known for promoting T cell survival and clonal expansion while inhibiting the suppressive effects of regulatory T cells (Tregs). This specific second-generation CAR-T cell structure is designed to enhance the metabolic adaptability and persistence of CAR-T cells, making them particularly effective in complex environments where T cell exhaustion and rapid turnover are common challenges.

The application of scFv(EPCAM)-OX40-CD3zeta CAR-T lentivirus is primarily focused on the development and optimization of immunotherapy for solid tumors. EpCAM is a transmembrane glycoprotein frequently overexpressed in various cancer tissues, including lung, breast, colon, pancreatic, and prostate cancers, while its expression level is extremely low in normal epithelial tissues. This differential expression profile makes these lentiviral particles an important tool for researchers to validate EpCAM as a viable therapeutic target in adoptive cell therapy. In a laboratory setting, these lentiviral particles are used to generate CAR-T cells for rigorous in vitro cytotoxicity assays to evaluate the ability of engineered cells to recognize and eliminate EpCAM-positive cancer cell lines. Furthermore, this product is crucial for in vivo preclinical modeling, enabling scientists to evaluate CAR-T cell homing, invasion, and antitumor efficacy in complex tumor microenvironments using cell line-derived or patient-derived xenograft mouse models. In addition to directly killing tumor cells, OX40-based constructs are frequently used to study T-cell memory formation and lineage exhaustion prevention, thereby gaining a deeper understanding of how different co-stimulatory signals affect the durability of immune responses. It is also a key component of combination therapy research, used to investigate the synergistic effects of CAR-T cells with other therapies, such as immune checkpoint inhibitors, radiotherapy, or targeted small molecule drugs.